A SYSTEMATIC REVIEW OF ONCE-WEEKLY INSULIN ICODEC AS A NEW TREATMENT FOR TYPE 1 DIABETES MELLITUS
Main Article Content
Keywords
Once-weekly insulin icodec, Type 1 Diabetes Mellitus, Glycemic control, Clinical trial data, HbA1c levels, Pharmacokinetics, Patient adherence, Adverse events, Systematic review, Insulin regimens
Abstract
Purpose: This study aims to evaluate the efficacy and safety of once-weekly insulin codec as a novel treatment for type 1 diabetes mellitus (T1DM) using insights from clinical trial data.
Design/Methodology/Approach: The research employed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) methodology. A comprehensive search was conducted across PubMed, Scopus, and Web of Science databases for English-language studies published between 2000 and 2023. Out of 2,567 citations identified, 45 studies were included in the final analysis.
Findings: The analysis revealed a significant correlation between once-weekly insulin codec and improved glycemic control in T1DM patients. Specifically, 60% of the studies reported notable reductions in HbA1c levels. In contrast, 25% of the studies found no significant difference compared to daily insulin regimens, while 15% observed a slight increase in adverse events, such as hypoglycemia. Additional studies provided insights into the pharmacokinetics and patient adherence associated with once-weekly insulin codec, highlighting its potential to enhance patient compliance and quality of life. The year 2021 was identified as the most productive, with several key publications detailing the clinical benefits and safety profile of the treatment.
Practical Implications: The findings could inform healthcare providers and policymakers about adopting a once-weekly insulin codec as a feasible treatment option for T1DM, potentially leading to improved patient adherence and outcomes.
Originality/Value: This study is a pioneering effort to provide a comprehensive examination of the once-weekly insulin codec for T1DM using the systematic literature review (SLR) methodology.
References
2. Bajaj, H. S., Aberle, J., Davies, M., Donatsky, A. M., Frederiksen, M., Yavuz, D. G., Gowda, A., Lingvay, I., & Bode, B. (2023). Once-weekly insulin codec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5) a randomized trial. Annals of Internal Medicine, 176(11), 1476-1485.
3. Bajaj, H. S., Bergenstal, R. M., Christoffersen, A., Davies, M. J., Gowda, A., Isendahl, J., Lingvay, I., Senior, P. A., Silver, R. J., & Trevisan, R. (2021). Switching to once-weekly insulin codec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care, 44(7), 1586-1594.
4. Kosmeri, C., Baltogianni, M., Giapros, V., Siomou, E., Tsinopoulou, V.-R., Balomenou, F., & Serbis, A. (2024). Which Diabetes Patients Will Benefit the Most from Once-Weekly Basal Insulin Analogs? A Review with a Special Focus on Type 1 Diabetes Patients. Endocrines, 5(2), 214-224.
5. Lingvay, I., Asong, M., Desouza, C., Gourdy, P., Kar, S., Vianna, A., Vilsbøll, T., Vinther, S., & Mu, Y. (2023). Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA, 330(3), 228-237.
6. Lingvay, I., Buse, J. B., Franek, E., Hansen, M. V., Koefoed, M. M., Mathieu, C., Pettus, J., Stachlewska, K., & Rosenstock, J. (2021). A randomized, open-label comparison of once-weekly insulin codec titration strategies versus once-daily insulin glargine U100. Diabetes Care, 44(7), 1595-1603.
7. Mathieu, C., Ásbjörnsdóttir, B., Bajaj, H. S., Lane, W., Matos, A. L. S., Murthy, S., Stachlewska, K., & Rosenstock, J. (2023). Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. The Lancet, 401(10392), 1929-1940.
8. Ribeiro, S. A. G., Chavez, M. P., Hespanhol, L. C., Balieiro, C. C. A., Paqualotto, E., e Silva, R. R., Gauza, M., & de Sa, J. R. (2024). Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis. Metabolism Open, 100285.
9. Rosenstock, J., Bain, S. C., Gowda, A., Jódar, E., Liang, B., Lingvay, I., Nishida, T., Trevisan, R., & Mosenzon, O. (2023). Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. New England Journal of Medicine, 389(4), 297-308.
10. Rosenstock, J., Bajaj, H. S., Janež, A., Silver, R., Begtrup, K., Hansen, M. V., Jia, T., & Goldenberg, R. (2020). Once-weekly insulin for type 2 diabetes without previous insulin treatment. New England Journal of Medicine, 383(22), 2107-2116.
11. Saleem, S. Z., Fareed, A., Akhtar, S. M. M., Farhat, S., Taha, A. M., & Akilimali, A. (2024). Efficacy and safety of once-weekly insulin codec compared to once-daily insulin g U-100 in patients with type II diabetes: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome, 16(1), 80.
12. Shah, A. S., & Wolf, R. M. (2023). Weekly insulin: a paradigm shift in type 1 diabetes therapy. The Lancet, 402(10413), 1598-1599.
13. Silva, R. R. e., Gauza, M. d. M., Guisso, M. E. S., Silva, J. O. N. d., & Kohara, S. K. (2023). Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials. Archives of Endocrinology and Metabolism, 67(5), e000614.
14. Singh, A. K., Singh, A., Singh, R., & Misra, A. (2022). Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 16(9), 102615.
15. Soetedjo, N. N. M., Permana, H., Hariyanto, T. I., Tendean, M., Kusumawati, M., Ritonga, E., Yanto, T. A., & Suastika, K. (2023). Once-weekly insulin codec as a novel treatment for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, 110984.
16. Soetedjo, N. N. M., Permana, H., Hariyanto, T. I., Tendean, M., Kusumawati, M., Ritonga, E., Yanto, T. A., & Suastika, K. (2024). Once-weekly insulin as a novel treatment for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, 111630.
17. Trevisan, R., Conti, M., & Ciardullo, S. (2024). Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. Diabetologia, 1-13.
18. Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., & Jia, L. (2024). Efficacy and safety of once-weekly insulin regimes on glycemic control for type 2 diabetes: a systematic review and network meta-analysis. Diabetology & Metabolic Syndrome, 16(1), 3.
19. Wang, X., Xiao, W., Liang, Z., Li, S., & Tang, Q. (2023). Efficacy and safety of once-weekly basal insulin versus once-daily basal insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine, 102(52), e36308.
20. Zakaria, F., Naveed, A. K., Ahmed, M., Rao, R., Shaikh, A., Farid, A. A. M., Ali, T., & Hasanain, M. (2023). Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 for type 2 diabetes in insulin naive patients: a systemic review and meta-analysis. Diabetes Epidemiology and Management, 100181.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Krisli Serani
Anesthesia and Reanimation Specialist, Anaesthesia and Intensive Care Unit, University of Medicine Tirana Albania/ Memorial Hospital Fier Albania, Albania
Saeed Ur Rehman
Resident CPSP Medicine and Allied (Dermatology), Dermatology Unit, MTI Khyber Teaching Hospital Peshawar, Pakistan
Riad A.Kouzeiha
Medical Student, Faculty of Medical Sciences, Lebanese University, Hadath Campus, Beirut, Lebanon
Mansoor Khan
Trainee Medical Officer (TMO), Plastic, Reconstructive Surgery and Burn Unit, Ayub Teaching Hospital Abbottabad, Pakistan
Naseem Akhter
Assistant Editor, Research journal of Innovative Ideas and Thoughts
Muhammad Asfandiyar Ali
Senior House Officer, Department of General Medicine, Mayo University Hospital, Ireland
Shuja Ullah
Senior House Officer, Department of General Medicine, Mayo University Hospital, Ireland
Mohammad Yassin
Medical Student, Faculty of Medical Science, Lebanese University, Lebanon,